FDA's Center for Drug Evaluation and Research brought its novel agent approvals count for 2017 to nine with the clearance of Pfizer Inc. and EMD Serono Inc.'s immuno-oncologic Bavencio (avelumab), Newron Pharmaceuticals SPA's neurology drug Xadago (safinamide), and Shionogi & Co. Ltd.'s opioid-induced constipation treatment Symproic (naldemedine) over a three-day period. Here's your news in brief:
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?